Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

Authors: Armando Santoro, Garrido Pilar, Daniel S.W. Tan, Jon Zugazagoitia, Frances A. Shepherd, Alessandra Bearz, Fabrice Barlesi, Tae Min Kim, Tobias R. Overbeck, Enriqueta Felip, Can Cai, Simantini Eddy, Tracey McCulloch, Eric S. Schaefer

Source: BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)

Subject Terms: Canakinumab, NSCLC, PD-L1, Platinum-doublet chemotherapy, Spartalizumab, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/49d4a4474e494f5081ff231d7fc7b4f8

Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction

Authors: Enriqueta Felip, Paolo Nuciforo, Elena Garralda, Joan Frigola, Ramon Amat, Garazi Serna, Francesco Grussu, Kinga Bernatowicz, Olivia Prior, Marta Ligero, Christina Zatse, Rodrigo Toledo, Manel Escobar, Raquel Perez-Lopez

Source: Journal for ImmunoTherapy of Cancer, Vol 13, Iss 1 (2025)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://jitc.bmj.com/content/13/1/e009140.full; https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/b5156977bb144aee8b8a3bbf43ebe032

Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING study

Authors: Elisabetta Petracci, Luigi Pasini, Milena Urbini, Enriqueta Felip, Franco Stella, Fabio Davoli, Maurizio Salvi, Michele Beau-Faller, Michela Tebaldi, Irene Azzali, Matteo Canale, Piergiorgio Solli, Giulia Lai, Ramon Amat, Caterina Carbonell, Pierre-Emmanuel Falcoz, Alex Martinez-Marti, Erwan Pencreach, Angelo Delmonte, Lucio Crinò, Paola Ulivi

Source: Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-14 (2024)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1756-9966

Access URL: https://doaj.org/article/a21e55c42e3a48e29c60494710709dba

First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study

Authors: Aida Piedra, Sergio Martínez-Recio, Ainhoa Hernández, Teresa Morán, Edurne Arriola, Jordi Recuero-Borau, Manuel Cobo, Patricia Cordeiro, Joaquín Mosquera, Manuel Fernández, Rosario García-Campelo, Antonio Calles, Rosa Álvarez, María Zapata-García, Dolores Isla, Ana Callejo, Patricia Iranzo, Jorgina Serra-López, Andrés Barba, Ivana Sullivan, Enriqueta Felip, Margarita Majem

Source: Frontiers in Oncology, Vol 14 (2024)

Subject Terms: pembrolizumab, non-small cell lung cancer, first-line, predictive factors, high PD-L1 expression, immune check-point inhibitors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1510278/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/5bddfd2fdb244305bbfcb2496d8d7880

Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational studyResearch in context

Authors: Oriol Mirallas, Berta Martin-Cullell, Víctor Navarro, Kreina Sharela Vega, Jordi Recuero-Borau, Diego Gómez-Puerto, Daniel López-Valbuena, Clara Salva de Torres, Laura Andurell, Anna Pedrola, Roger Berché, Fiorella Palmas, José María Ucha, Guillermo Villacampa, Alejandra Rezqallah, Judit Sanz-Beltran, Rafael Bach, Sergio Bueno, Cristina Viaplana, Gaspar Molina, Alberto Hernando-Calvo, Juan Aguilar-Company, María Roca, Eva Muñoz-Couselo, Alex Martínez-Martí, Ada Alonso, Simeon Eremiev, Teresa Macarulla, Ana Oaknin, Cristina Saura, Elena Élez, Enriqueta Felip, Ángeles Peñuelas, Rosa Burgos, Patricia Gómez Pardo, Elena Garralda, Josep Tabernero, Sònia Serradell, Sònia Servitja, David Paez, Rodrigo Dienstmann, Joan Carles

Source: The Lancet Regional Health. Europe, Vol 46, Iss , Pp 101063- (2024)

Subject Terms: Prognostic factors, Hospital oncology service, 90-day mortality, PROMISE tool, LASSO method, Public aspects of medicine, RA1-1270

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666776224002308; https://doaj.org/toc/2666-7762

Access URL: https://doaj.org/article/510c740dd59f414d89fc0806c8cb60c4

Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study

Authors: Joel W. Neal, MD, PhD, Armando Santoro, MD, Maria Gonzalez-Cao, MD, PhD, Farah Louise Lim, MRCP, MD, Bruno Fang, MD, Ryan D. Gentzler, MD, MS, Jerome Goldschmidt, MD, Polina Khrizman, MD, Claudia Proto, MD, Shiven Patel, MD, MBA, FACP, Sonam Puri, MD, Stephen V. Liu, MD, Erminia Massarelli, MD, PhD, MS, Denise Williamson, MPH, Martin Schwickart, PhD, Christian Scheffold, MD, PhD, Svetlana Andrianova, MD, MPH, Enriqueta Felip, MD, PhD

Source: JTO Clinical and Research Reports, Vol 5, Iss 10, Pp 100666- (2024)

Subject Terms: Cabozantinib, Atezolizumab, Non–small cell lung cancer, Immunotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364324000365; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/6812448f29344fa6a786793805d199c0

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial

Authors: Benjamin J. Solomon, M.B.B.S., PhD, Ibiayi Dagogo-Jack, MD, Se-Hoon Lee, MD, Michael J. Boyer, M.B.B.S., PhD, Suresh S. Ramalingam, MD, Enric Carcereny, MD, Enriqueta Felip, MD, PhD, Ji-Youn Han, MD, PhD, Toyoaki Hida, PhD, Brett G.M. Hughes, M.B.B.S., Sang-We Kim, MD, PhD, Makoto Nishio, MD, PhD, Takashi Seto, MD, Tatsuro Okamoto, MD, PhD, Xiaoxi Zhang, PhD, Jean-Francois Martini, PhD, Erjian Wang, MD, PhD, Steven De Beukelaer, MD, Todd M. Bauer, MD

Source: JTO Clinical and Research Reports, Vol 5, Iss 7, Pp 100685- (2024)

Subject Terms: Non–small cell lung cancer, Avelumab, Lorlatinib, Crizotinib, Phase 1b/2, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364324000559; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/50d39c846b474baea88547c6b345e6aa

Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

Authors: Armando Santoro, Garrido Pilar, Daniel S.W. Tan, Jon Zugazagoitia, Frances A. Shepherd, Alessandra Bearz, Fabrice Barlesi, Tae Min Kim, Tobias R. Overbeck, Enriqueta Felip, Can Cai, Simantini Eddy, Tracey McCulloch, Eric S. Schaefer

Source: BMC Cancer, Vol 24, Iss 1, Pp 1-1 (2024)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/7ffe7831669f4ee5abb317e48ceb96ea

The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project

Authors: Valeria Sebri, Chiara Marzorati, Patrizia Dorangricchia, Dario Monzani, Roberto Grasso, Arsela Prelaj, Leonardo Provenzano, Laura Mazzeo, Andra Diana Dumitrascu, Jana Sonnek, Marlen Szewczyk, Iris Watermann, Francesco Trovò, Nina Dollis, Evangelos Sarris, Marina Chiara Garassino, Christine M. Bestvina, Alessandra Pedrocchi, Emilia Ambrosini, Sokol Kosta, Enriqueta Felip, Mireia Soleda, Aina Arbusà Roca, Jose Rodríguez‐Morató, Alessandro Nuara, Yonah Lourie, Melissa Fernandez‐Pinto, Alfonso Aguaron, Gabriella Pravettoni

Source: Cancer Medicine, Vol 13, Iss 9, Pp n/a-n/a (2024)

Subject Terms: anxiety, decision‐making, non‐small cell lung cancer, patient knowledge, treatment consultation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/ed074b66fd67427fb27af9774867cbe3

RET Fusion Testing in Patients With NSCLC: The RETING Study

Authors: Esther Conde, MD, PhD, Susana Hernandez, PhD, Jose Luis Rodriguez Carrillo, MD, Rebeca Martinez, APT, Marta Alonso, APT, Daniel Curto, MD, Beatriz Jimenez, MD, Alejandra Caminoa, MD, PhD, Amparo Benito, MD, Pilar Garrido, MD, PhD, Sergi Clave, PhD, Edurne Arriola, MD, PhD, Isabel Esteban-Rodriguez, MD, PhD, Javier De Castro, MD, PhD, Irene Sansano, MD, Enriqueta Felip, MD, PhD, Federico Rojo, MD, PhD, Manuel Dómine, MD, PhD, Ihab Abdulkader, MD, PhD, Jorge Garcia-Gonzalez, MD, Cristina Teixido, PhD, Noemi Reguart, MD, PhD, Desamparados Compañ, MD, PhD, Amelia Insa, MD, Nuria Mancheño, MD, PhD, Sarai Palanca, MD, PhD, Oscar Juan-Vidal, MD, PhD, Nuria Baixeras, MD, Ernest Nadal, MD, PhD, Maria Cebollero, MD, Antonio Calles, MD, Paloma Martin, MD, PhD, Clara Salas, MD, PhD, Mariano Provencio, MD, PhD, Ignacio Aranda, MD, PhD, Bartomeu Massuti, MD, Laura Lopez-Vilaro, MD, Margarita Majem, MD, PhD, Luis Paz-Ares, MD, PhD, Fernando Lopez-Rios, MD, PhD

Source: JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100653- (2024)

Subject Terms: RET fusions, Next-generation sequencing, FISH, RT-PCR, Lung carcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364324000237; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/a3e58ca9d39948fda3972ff1d75a8f34

Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study

Authors: Maria-Josep Carreras, Elena Tomás-Guillén, Anna Farriols, Berta Renedo-Miró, Carolina Valdivia, Jana Vidal, Cristina Saura, Joan Carles, Enriqueta Felip, Maria-Queralt Gorgas, Josep Tabernero, Josep Monterde

Source: Current Oncology, Vol 30, Iss 9, Pp 7984-8004 (2023)

Subject Terms: cancer, expenditure, antineoplastic agents, solid tumors, supportive care, retrospective cohort study, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.mdpi.com/1718-7729/30/9/580; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729

Access URL: https://doaj.org/article/693da0fcbdaa4f0cad78276db01bf51c

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Authors: Enriqueta Felip, David P. Carbone, Martin Reck, Luis Paz-Ares, Yong Yuan, Nan Hu, Niels Reinmuth, Xiaoqing Zhang, Thomas John, Ying Cheng, Shun Lu, Manuel Cobo, Michael Schenker, Tudor-Eliade Ciuleanu, Stéphanie Bordenave, Oscar Juan-Vidal, Juliana Menezes, Eduardo Richardet, Hideaki Mizutani, Bogdan Zurawski, Aurelia Alexandru, Javed Mahmood, Tuli De, Irene Santi, John R. Penrod, Adam Lee

Source: Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://jitc.bmj.com/content/12/2/e008189.full; https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/c372aee3045841d7bf925f1ae98c8480

The expanding importance of tissue sample analysis for biomarker testing in non-small cell lung cancer management and survival

Authors: Augusto Valdivia, Ilaria Priano, Nuria Pardo, Enriqueta Felip

Source: Barcelona Respiratory Network Reviews, Vol 10, Iss 1 (2024)

Subject Terms: Biomarkers. Immunotherapy. Non-small-cell lung cancer. Targeted therapy., Diseases of the respiratory system, RC705-779

File Description: electronic resource

Relation: https://www.brnreviews.com/frame_eng.php?id=245; https://doaj.org/toc/2462-3172

Access URL: https://doaj.org/article/d600cb5f789a42a399489af6661de192

Symptoms and Experiences with Small Cell Lung Cancer: A Mixed Methods Study of Patients and Caregivers

Authors: D. Gwyn Bebb, Cressida Murray, Andromachi Giannopoulou, Enriqueta Felip

Source: Pulmonary Therapy, Vol 9, Iss 3, Pp 435-450 (2023)

Subject Terms: Caregiver, Interview, Mixed methods, Patient-reported outcome, Qualitative, Small cell lung cancer, Diseases of the respiratory system, RC705-779

File Description: electronic resource

Relation: https://doaj.org/toc/2364-1754; https://doaj.org/toc/2364-1746

Access URL: https://doaj.org/article/8317d390659f4377b1ef8a86db66a285

Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC

Authors: Caterina Carbonell, Joan Frigola, Nuria Pardo, Ana Callejo, Patricia Iranzo, Augusto Valdivia, Ilaria Priano, Susana Cedrés, Alex Martinez‐Marti, Alejandro Navarro, Laura Lenza, Mireia Soleda, Javier Gonzalo‐Ruiz, Ana Vivancos, Miriam Sansó, Enric Carcereny, Teresa Morán, Ramon Amat, Enriqueta Felip

Source: Molecular Oncology, Vol 17, Iss 5, Pp 779-791 (2023)

Subject Terms: aneuploidy, cfDNA, immune checkpoint inhibitors, liquid biopsy, NSCLC, shallow whole‐genome sequencing, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1574-7891; https://doaj.org/toc/1878-0261

Access URL: https://doaj.org/article/604e6cdc2d234a06b5347b1a01ff2632

595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab

Authors: Enriqueta Felip, Christian Mueller, Martin Forster, Tim Clay, Matthew Krebs, Frederic Triebel, Enric Carcereny, Ewa Kalinka, Margarita Majem, Bernard Doger, Julio Peguero, Chrystelle Brignone, Igor Bondarenko, Wade T Iams, Manuel Cobo Dols, Grygorii Ursol, Gema Garcia Ledo, Laia Vilà Martinez

Source: Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/6b475fde214d41829d313ffd4989b729

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial

Authors: Enriqueta Felip, Hiroshi Tanaka, Silvia Novello, Hao Xu, Heather Wakelee, Barbara Gitlitz, Martin Reck, Wei Zou, Elizabeth Bennett, Mark McCleland, Caicun Zhou, Satoshi Oizumi, Anna Kryzhanivska, Virginia McNally, Marcus Ballinger, Meghna Das Thakur, Steven L McCune, John Hamm, Minu K Srivastava, Nasser Altorki, Rüdiger Liersch

Source: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://jitc.bmj.com/content/11/10/e007047.full; https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/cfe63add9cfe46b48a019fc54672b05f

A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer

Authors: Benjamin Solomon, Ana Callejo, Jair Bar, Guy Berchem, Lyudmila Bazhenova, Pierre Saintigny, Fanny Wunder, Jacques Raynaud, Nicolas Girard, J. Jack Lee, Raed Sulaiman, Bruce Prouse, Catherine Bresson, Hila Ventura, Shai Magidi, Eitan Rubin, Brandon Young, Amir Onn, Brian Leyland‐Jones, Richard L. Schilsky, Vladimir Lazar, Enriqueta Felip, Razelle Kurzrock

Source: Cancer Medicine, Vol 11, Iss 14, Pp 2790-2800 (2022)

Subject Terms: anti‐PD‐L1, CDK4/6, genomics, NSCLC, phase I, transcriptomics, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/9a1795592c8e42cab3df58cfe6f8ac80

A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology

Authors: Vladimir Lazar, Baolin Zhang, Shai Magidi, Christophe Le Tourneau, Eric Raymond, Michel Ducreux, Catherine Bresson, Jacques Raynaud, Fanny Wunder, Amir Onn, Enriqueta Felip, Josep Tabernero, Gerald Batist, Razelle Kurzrock, Eitan Rubin, Richard L. Schilsky

Source: Therapeutic Advances in Medical Oncology, Vol 15 (2023)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1758-8359

Access URL: https://doaj.org/article/59159a57b2d143e3be0bcdbaf9afc021

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Authors: Enriqueta Felip, Helena Linardou, Fabrice Barlesi, Michele Maio, Luis Paz-Ares, Jonathan W Goldman, Karim Vermaelen, Osvaldo Arén Frontera, Erika Rijavec, Kevin Jao, Clarisse Audigier-valette, Han Chang, David R Spigel, Neal E Ready, Tudor-Eliade Ciuleanu, María Rosario García Campelo, Stéphanie Bordenave, Laszlo Urban, Jean-Sébastien Aucoin, Cristina Zannori, Alessandra Curioni Fontecedro, Amparo Sánchez-Gastaldo, Oscar Juan-Vidal, Elena Poddubskaya, Samreen Ahmed, Sunney Li, Joseph Fiore, Angelic Acevedo

Source: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://jitc.bmj.com/content/11/2/e006127.full; https://doaj.org/toc/2051-1426

Access URL: https://doaj.org/article/299f8904a44340aa8e9fdf450ecbbc4b